These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34787835)

  • 1. Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
    Nakamae M; Nakamae H; Hashimoto M; Koh H; Nakashima Y; Hirose A; Hino M
    Int J Hematol; 2022 Mar; 115(3):329-335. PubMed ID: 34787835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
    Matsumura I
    Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
    Miyazaki S
    Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
    Malkan UY; Haznedaroglu IC
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
    Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.
    Ross DM; Arthur C; Burbury K; Ko BS; Mills AK; Shortt J; Kostner K
    Intern Med J; 2018 Feb; 48 Suppl 2():5-13. PubMed ID: 29388307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by the Systematic Coronary Risk Estimation 2 algorithm.
    Szczepanek E; Marczyk B; Chukwu O; Chlopicki S; Sacha T
    Pol Arch Intern Med; 2024 Jun; 134(6):. PubMed ID: 38572907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
    Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
    Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
    Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
    Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
    Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
    Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
    Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Molica M; Alimena G
    Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial hypertension assessment in a population with chronic myeloid leukemia.
    Roa-Chamorro R; Jaén-Águila F; Puerta-Puerta JM; Torres-Quintero L; González-Bustos P; Mediavilla-García JD
    Sci Rep; 2021 Jul; 11(1):14637. PubMed ID: 34282224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifelong TKI therapy: how to manage cardiovascular and other risks.
    Mauro MJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):113-121. PubMed ID: 34889360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.